FOLFOXIRI联合贝伐珠单抗对比双药联合贝伐珠单抗一线治疗不可切除转移性结直肠癌的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入5项随机试验共1697例不可切除转移性结直肠癌患者,比较FOLFOXIRI联合贝伐珠单抗与双药联合贝伐珠单抗一线治疗。
要点
- FOLFOXIRI联合贝伐珠单抗较双药联合贝伐珠单抗显著改善OS(HR 0.81)。
- PFS、ORR和R0切除率均显著提高,但3/4级毒性增加。
- BRAF突变患者未观察到额外获益。
核心结论
- FOLFOXIRI联合贝伐珠单抗较双药联合贝伐珠单抗显著且具有临床意义地改善转移性结直肠癌患者的总生存期。
- 该方案在PFS、ORR和R0切除率方面具有优势,但毒性反应中度增加。
- BRAF突变肿瘤患者未观察到获益增加。
研究设计与样本
- 个体患者数据荟萃分析,纳入5项 eligible 试验(CHARTA、OLIVIA、STEAM、TRIBE、TRIBE2)。
- 共1697例患者随机分配至FOLFOXIRI联合贝伐珠单抗组(n=846)或双药联合贝伐珠单抗组(n=851)。
- 主要终点为总生存期,次要终点包括PFS、ORR、R0切除率、3/4级不良事件及亚组分析。
临床怎么用
- 对于不可切除转移性结直肠癌的一线治疗,FOLFOXIRI联合贝伐珠单抗可作为双药联合贝伐珠单抗的替代方案,尤其适用于适合强化治疗且能耐受较高毒性的患者。
- 治疗决策时应权衡生存获益与毒性增加,特别是3/4级中性粒细胞减少、发热性中性粒细胞减少和腹泻的风险。
- BRAF突变患者可能无法从FOLFOXIRI联合贝伐珠单抗中获得额外生存获益,需个体化考虑。
局限性
- 研究纳入的5项试验主要终点并非OS,但通过个体患者数据荟萃分析提高了检验效能。
- 未发现治疗与所研究特征的显著交互作用,但亚组分析可能受样本量限制。
- 毒性反应增加可能影响患者耐受性和生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A proper estimation of the magnitude of the overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + bevacizumab is lacking because all trials that have investigated this regimen had primary end points other than OS. To test OS with higher power and to explore the interaction of treatment effect with main patient and disease characteristics, we performed an individual patient data (IPD) meta-analysis. PATIENTS AND METHODS: IPD from 5 eligible trials were collected: CHARTA (ClinicalTrials.gov identifier: NCT01321957), OLIVIA (ClinicalTrials.gov identifier: NCT00778102), STEAM (ClinicalTrials.gov identifier: NCT01765582), TRIBE (ClinicalTrials.gov identifier: NCT00719797), and TRIBE2 (ClinicalTrials.gov identifier: NCT02339116). The primary end point was OS. Secondary end points were progression-free survival (PFS), objective response rate (ORR), R0 resection rate, grade 3/4 adverse events, and subgroup analyses according to clinical and molecular characteristics. RESULTS: A total of 1,697 patients were randomly assigned to FOLFOXIRI + bevacizumab (n = 846) or doublets + bevacizumab (n = 851). Most (78%) had an Eastern Cooperative Oncology Group performance status of 0, and the median age was 61 years. After a median follow-up of 39.9 months, patients assigned to FOLFOXIRI + bevacizumab had significantly longer OS than those assigned to doublets + bevacizumab (median, 28.9 v 24.5 months; hazard ratio [HR], 0.81; 95% CI, 0.72 to 0.91; P < .001), with no significant heterogeneity among trials (P = .39; I2 = 2%). No significant interaction effect between treatment arm and investigated characteristics was demonstrated. Patients assigned to FOLFOXIRI + bevacizumab had longer PFS (median, 12.2 v 9.9 months; HR, 0.74; 95% CI, 0.67 to 0.82; P < .001), higher ORR (64.5% v 53.6%; P < .001), higher R0 resection rate (16.4% v 11.8%; P = .007), and higher rates of grade 3/4 neutropenia (45.8% v 21.5%; P < .001), febrile neutropenia (6.3% v 3.7%; P = .019), and diarrhea (17.8% v 8.4%; P < .001). CONCLUSION: FOLFOXIRI + bevacizumab significantly and meaningfully improves survival of patients with metastatic colorectal cancer compared with doublets + bevacizumab and provides advantage in PFS, ORR, and R0 resection rate at the price of a moderate increase in toxicity. No increased benefit is observed among patients with BRAF-mutant tumors.
引用
- Cremolini C, Antoniotti C, Stein A, et al. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol. 2020. PMID: 32816630. doi:10.1200/JCO.20.01225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。